More than 50 memory clinics across the U.K. are now offering simple blood tests to thousands of people worried about their memory — a potential turning point in how dementia is detected and treated. The five-year trial, led by researchers at the University of Oxford and University College London, aims to test whether cheap, minimally invasive blood tests can detect the protein markers of early-stage dementia as reliably as they do in controlled research settings.
At a glance
- Blood tests for dementia: More than 50 U.K. memory clinics will offer tests to approximately 5,000 volunteers over five years, screening for protein biomarkers linked to Alzheimer’s and other forms of dementia.
- Alzheimer’s diagnosis gap: Around one in three people living with dementia in England has never received a formal diagnosis — and currently only 2% of those with dementia can access the specialized tests needed to qualify for newer treatments.
- Trial funding: The research is sponsored by Alzheimer’s Research UK and the Alzheimer’s Society, backed by £5 million from the People’s Postcode Lottery.
Why the current system is failing people
Getting a dementia diagnosis in the U.K. today is slow, painful, and often inaccessible. The standard route involves mental ability tests, brain scans, or lumbar punctures — a procedure that draws fluid from the lower back and carries real discomfort and risk.
Charities report that patients and families can wait up to four years for an appointment and results. Meanwhile, roughly 1 million people in Britain are living with dementia, a number projected to reach 1.7 million by 2040 C.E. In 2022 C.E., dementia caused the deaths of 66,000 people in England and Wales, making it the leading cause of death in the country, with Alzheimer’s disease accounting for two-thirds of cases.
Fiona Carragher, director of research and influencing at the Alzheimer’s Society, put it plainly: “Dementia is the U.K.’s biggest killer, yet a third of people living with dementia don’t have a diagnosis, which means they’re not able to access care and support.”
What these blood tests could change
The trials are structured in two parts. The first, led by Jonathan Schott, chief medical officer at Alzheimer’s Research UK, will focus on the single most promising blood biomarker in a cohort of 1,100 people. The second will screen for multiple forms of dementia — including vascular dementia, frontotemporal dementia, and dementia with Lewy bodies — across roughly 4,000 participants.
If the tests perform in clinical settings as well as they have in research environments, they could dramatically compress the diagnostic timeline. That matters not only for patients seeking clarity and support, but also for access to a new generation of Alzheimer’s treatments — drugs that work best when started early, during the disease’s earliest detectable stages.
Dr. Sheona Scales, director of research at Alzheimer’s Research UK, noted that blood-based diagnostics have already made a measurable difference in other disease areas. “We need to see this same step change in dementia,” she said, “which is the greatest health challenge facing the U.K.”
A window into the science
The biomarkers being tested are proteins that accumulate in the brain during the early stages of neurodegeneration — some years, even decades, before symptoms become obvious. Detecting them in the bloodstream rather than through cerebrospinal fluid analysis is a significant simplification. Current NHS diagnostic pathways were not designed with scale in mind, and the tests being trialed here could eventually be run through a standard blood draw at a GP’s office.
The research teams at Alzheimer’s Research UK have emphasized that the goal is not just earlier diagnosis for its own sake, but creating a pathway that connects patients to treatment options that currently remain out of reach for most. Only 2% of people with dementia in the U.K. currently access the specialized tests needed to demonstrate eligibility for the newest therapies.
Still a long road ahead
The trial is a significant step, but it is not a solution — not yet. Even if the blood tests prove reliable across diverse real-world populations, rolling them out routinely on the National Health Service will require policy decisions, funding commitments, and integration into existing care pathways that take time. Questions remain about what happens after diagnosis — whether the treatment infrastructure can scale to meet the need that better detection will inevitably reveal.
What the trial does offer, immediately, is something many people with memory concerns have not had: the chance to find out sooner, more easily, and with less suffering what is happening in their own minds. For the estimated 400,000 people in England living with undiagnosed dementia, that is not a small thing.
The University College London and University of Oxford collaboration represents one of the largest coordinated dementia diagnostic research efforts the U.K. has undertaken. The five-year window will determine whether a simpler, more humane path to diagnosis can become the norm — and whether it can get there before the projected surge in cases arrives.
Read more
For more on this story, see: The Guardian
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- Renewables now make up at least 49% of global power capacity
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-
COP30 pledges recognition of 160 million hectares of Indigenous land rights
At the COP30 World Leaders Summit in Belém, Brazil in November 2025, 15 governments pledged to formally recognize Indigenous land rights over 160 million hectares by 2030 — an area the size of Iran — through the Intergovernmental Land Tenure Commitment. Brazil committed at least 59 million hectares. More than 35 donors renewed a $1.8 billion Forest and Land Tenure Pledge. The Tropical Forest Forever Facility secured nearly $7 billion, with 20% directed to Indigenous peoples. It was the largest Indigenous participation in COP history.
-
Ghana declares its first marine protected area to rescue depleted fish stocks
Ghana’s marine protected area — the country’s first ever — marks a historic turning point for a nation gripped by a quiet fisheries crisis. Established near Cape Three Points in the Western Region, the protected zone restricts or bans fishing activity to allow severely depleted fish populations to recover. Ghana’s coastal stocks have fallen by an estimated 80 percent from historic levels, threatening food security and the livelihoods of millions of small-scale fishers. The declaration also carries regional significance, potentially inspiring neighboring Gulf of Guinea nations to establish coordinated protections of their own.
-
U.S. researchers cut Alzheimer’s risk by half in first-ever prevention trial
Alzheimer’s prevention may have reached a turning point after a landmark trial showed that removing amyloid plaques before symptoms appear can cut the risk of developing the disease by roughly 50%. Researchers at Washington University School of Medicine studied people with rare genetic mutations that make Alzheimer’s nearly inevitable, finding that early, aggressive treatment can genuinely alter the disease’s course. The results, published in The Lancet Neurology, mark the first time any intervention has shown potential to prevent Alzheimer’s from appearing at all, not merely slow its progression. That distinction matters enormously, since amyloid begins accumulating in the brain two…
